UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.253-254

2020

Volltextzugriff (PDF)

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.279-280

2020

Volltextzugriff (PDF)

Patterns of Growth Factor Costs in Multiple Myeloma Patients Treated With Lenalidomide or Bortezomib

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e259-e260

2015

Volltextzugriff (PDF)

Frequency Of Protease Activated Receptor1 (PAR1) Expression And The In Vitro Effects Of XT5 And XT2B, Two Novel PAR1 Binding Molecules, On Primary And Bortezomib Refractory Myeloma Cell Lines

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e235-e235

2015

Volltextzugriff (PDF)

Defining and treating high-risk multiple myeloma

Leukemia, 2015-11, Vol.29 (11), p.2119-2125

2015

Volltextzugriff (PDF)

CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Value in health, 2023-12, Vol.26 (12), p.S37

2023

Volltextzugriff (PDF)

P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Value in health, 2023-12, Vol.26 (12), p.S5

2023

Volltextzugriff (PDF)

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

Leukemia, 2012-11, Vol.26 (11), p.2398-2405

2012

Volltextzugriff (PDF)

P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Value in health, 2023-12, Vol.26 (12), p.S5-S6

2023

Volltextzugriff (PDF)

CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Value in health, 2023-12, Vol.26 (12), p.S31

2023

Volltextzugriff (PDF)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Leukemia, 2014-12, Vol.28 (12), p.2410-2413

2014

Volltextzugriff (PDF)

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

Leukemia, 2013-12, Vol.27 (12), p.2269-2271

2013

Volltextzugriff (PDF)

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Bone marrow transplantation (Basingstoke), 2016-01, Vol.51 (1), p.58-66

2016

Volltextzugriff (PDF)

Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)

Annals of oncology, 2017-09, Vol.28, p.v356-v356

2017

Volltextzugriff (PDF)

PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB

Value in health, 2019-11, Vol.22, p.S501

2019

Volltextzugriff (PDF)

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

Leukemia, 2014-12, Vol.28 (12), p.2413-2415

2014

Volltextzugriff (PDF)

Insight into human protease activated receptor-1 as anticancer target by molecular modelling

SAR and QSAR in environmental research, 2015-10, Vol.26 (10), p.795-807

2015

Volltextzugriff (PDF)

PF620 COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL

HemaSphere, 2019-06, Vol.3 (S1), p.264-n/a

2019

Volltextzugriff (PDF)

S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

HemaSphere, 2019-06, Vol.3 (S1), p.364-n/a

2019

Volltextzugriff (PDF)

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D‐RD) VS RD: MAIA

HemaSphere, 2019-06, Vol.3 (S1), p.255-n/a

2019

Volltextzugriff (PDF)

Therapy-related myeloid malignancies in myeloma

Mediterranean journal of hematology and infectious diseases, 2011, Vol.3 (1), p.e2011047-e2011047

2011

Volltextzugriff (PDF)

Preparation and characterization of activated carbon from a low rank coal

Carbon (New York), 1996, Vol.34 (1), p.77-82

1996

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(24)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(8)
Humans
(7)
Life Sciences & Biomedicine
(7)
Hematology
(6)
Oncology
(6)
Leukemia
(5)
Multiple Myeloma
(5)
Patient Outcomes
(4)
Patients
(4)
Care And Treatment
(3)
Female
(3)
Gene Expression
(3)
Gene Expression Profiling
(3)
Genetic Aspects
(3)
Male
(3)
Multiple Myeloma - Drug Therapy
(3)
Recurrence
(3)
Aged
(2)
Antineoplastic Agents - Therapeutic Use
(2)
Cancer
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

UPDATE OF CARTITUDE-1: A PHASE 1B/2 STUDY OF JNJ-68284528 (JNJ-4528), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR T (CAR-T) CELL THERAPY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Patterns of Growth Factor Costs in Multiple Myeloma Patients Treated With Lenalidomide or Bortezomib

Frequency Of Protease Activated Receptor1 (PAR1) Expression And The In Vitro Effects Of XT5 And XT2B, Two Novel PAR1 Binding Molecules, On Primary And Bortezomib Refractory Myeloma Cell Lines

Defining and treating high-risk multiple myeloma

CO129 Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy (RWPC) for Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

P20 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Vs Belantamab Mafodotin for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma

Heterogeneity of outcome with single-agent carfilzomib: all relapsed/refractory myelomas are not created equal

Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma

Split dosing of daratumumab (D) in a phase 1b study of D plus carfilzomib (K)-based regimens in patients (pts) with multiple myeloma (MM)

PCN334 ESTIMATING DIRECT COSTS AND PRODUCTIVITY COSTS ASSOCIATED WITH RAPID INFUSION OF DARATUMUMAB

Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma

Insight into human protease activated receptor-1 as anticancer target by molecular modelling

PF620 COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL

PF592 IMPACT OF AGE ON EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (D‐RD) IN PATIENTS WITH TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): MAIA

PF591 EFFICACY AND SAFETY OF DARATUMUMAB, LENALIDOMIDE, AND DEXAMETHASONE (D‐RD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED SUBGROUP ANALYSIS OF POLLUX BASED ON CYTOGENETIC RISK

S823 RANDOMIZED, OPEN‐LABEL, NON‐INFERIORITY, PHASE 3 STUDY OF SUBCUTANEOUS (SC) VERSUS INTRAVENOUS (IV) DARATUMUMAB (DARA) ADMINISTRATION IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: COLUMBA

PF603 FASTER & SUSTAINED IMPROVEMENT IN HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PTS TREATED WITH DARATUMUMAB, LENALIDOMIDE & DEXAMETHASONE (D‐RD) VS RD: MAIA

Therapy-related myeloid malignancies in myeloma

Preparation and characterization of activated carbon from a low rank coal

Suchergebnisse filtern